Literature DB >> 28825370

Lentiviral Vector Promoter is Decisive for Aberrant Transcript Formation.

Simone J Scholz1, Raffaele Fronza1,2, Cynthia C Bartholomä1, Daniela Cesana3, Eugenio Montini3, Christof von Kalle1, Irene Gil-Farina1, Manfred Schmidt1,2.   

Abstract

Lentiviral vectors hold great promise for the genetic correction of various inherited diseases. However, lentiviral vector biology is still not completely understood and warrants the precise decoding of molecular mechanisms underlying integration and post-translational modification. This study investigated a series of self-inactivating (SIN) and full long terminal repeat (LTR) lentiviral vectors that contained different types of promoters with or without a transgene to gain deeper insights in lentiviral target site selection and potential perturbation of cellular gene expression. Using an optimized nonrestrictive linear amplification-mediated polymerase chain reaction (nrLAM-PCR) protocol, vector structure-dependent integration site profiles were observed upon transduction of mouse lin- hematopoietic progenitors in vitro. Initial target site selection mainly depended on the presence of the promoter while being independent of its nature. Despite the increased propensity for read-through transcription of SIN lentiviral vectors, the incidence of viral-cellular fusion transcript formation involving the canonical viral splice donor or cryptic splice sites was reduced in both unselected primary lin- cells and transformed 32D cells. Moreover, the strength of the internal promoter in vectors with SIN LTRs is decisive for in vitro selection and for the abundance of chimeric transcripts, which are decreased by moderately active promoters. These results will help to better understand vector biology and to optimize therapeutic vectors for future gene therapy applications.

Entities:  

Keywords:  fusion transcripts; genotoxicity; integration site; lentiviral vectors

Mesh:

Year:  2017        PMID: 28825370     DOI: 10.1089/hum.2017.162

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  4 in total

1.  Aberrant Clonal Hematopoiesis following Lentiviral Vector Transduction of HSPCs in a Rhesus Macaque.

Authors:  Diego A Espinoza; Xing Fan; Di Yang; Stefan F Cordes; Lauren L Truitt; Katherine R Calvo; Idalia M Yabe; Selami Demirci; Kristin J Hope; So Gun Hong; Allen Krouse; Mark Metzger; Aylin Bonifacino; Rong Lu; Naoya Uchida; John F Tisdale; Xiaolin Wu; Suk See DeRavin; Harry L Malech; Robert E Donahue; Chuanfeng Wu; Cynthia E Dunbar
Journal:  Mol Ther       Date:  2019-04-09       Impact factor: 11.454

2.  Investigating the Barrier Activity of Novel, Human Enhancer-Blocking Chromatin Insulators for Hematopoietic Stem Cell Gene Therapy.

Authors:  Penelope-Georgia Papayanni; Nikoletta Psatha; Panayota Christofi; Xing-Guo Li; Pamela Melo; Monica Volpin; Eugenio Montini; Mingdong Liu; Georgios Kaltsounis; Minas Yiangou; David W Emery; Achilles Anagnostopoulos; Thalia Papayannopoulou; Suming Huang; George Stamatoyannopoulos; Evangelia Yannaki
Journal:  Hum Gene Ther       Date:  2021-10       Impact factor: 4.793

3.  Barcoding of Macaque Hematopoietic Stem and Progenitor Cells: A Robust Platform to Assess Vector Genotoxicity.

Authors:  Idalia M Yabe; Lauren L Truitt; Diego A Espinoza; Chuanfeng Wu; Samson Koelle; Sandhya Panch; Marcus A F Corat; Thomas Winkler; Kyung-Rok Yu; So Gun Hong; Aylin Bonifacino; Allen Krouse; Mark Metzger; Robert E Donahue; Cynthia E Dunbar
Journal:  Mol Ther Methods Clin Dev       Date:  2018-10-25       Impact factor: 6.698

4.  Predicting genotoxicity of viral vectors for stem cell gene therapy using gene expression-based machine learning.

Authors:  Adrian Schwarzer; Steven R Talbot; Anton Selich; Michael Morgan; Juliane W Schott; Oliver Dittrich-Breiholz; Antonella L Bastone; Bettina Weigel; Teng Cheong Ha; Violetta Dziadek; Rik Gijsbers; Adrian J Thrasher; Frank J T Staal; Hubert B Gaspar; Ute Modlich; Axel Schambach; Michael Rothe
Journal:  Mol Ther       Date:  2021-06-24       Impact factor: 11.454

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.